Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Core Insights - VolitionRx Limited is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, focusing on the use of Nu.Q® NETs for sepsis management [1][2] - The session will be chaired by Professor Djillali Annane, highlighting the potential clinical applications of Volition's Nu.Q® NETs H3.1 assay [2] - Research indicates that elevated levels of H3.1 nucleosomes could be critical in predicting organ failure and improving sepsis management [3] Company Overview - Volition is a multi-national epigenetics company dedicated to advancing early detection and monitoring of diseases, including sepsis [6][7] - The company is developing cost-effective blood tests aimed at diagnosing and monitoring various diseases, with a focus on improving patient outcomes [7] - Volition's research and development activities are based in Belgium, with additional offices in the U.S., London, and Singapore [8] Industry Context - Sepsis is identified as the leading cause of death in hospitals globally, accounting for at least 11 million deaths annually [5] - The symposium at ESICM Lives 2024 will gather experts from over 100 countries, emphasizing the global importance of advancements in sepsis management [5]